Zidovudine / Lamivudine + Nevirapine Twice Daily, Versus Tenofovir + Lamivudine + Nevirapine Once Daily in ARV-Naive Patients

Inclusion Criteria: HIV-1 infection, confirmed by a western-blot assay, at least 6 months after primary infection Age > or equal to 18 years of age No prior antiretroviral treatment Karnofsky superior to 60% CD4 T cells < 350/µL (2 measures, with at least a 1-month interval) in women, study will be proposed when CD4 cell count is below 250/µL, as nevirapine liver toxicity increases (X10) when CD4 are > 250/µL Written informed consent Exclusion Criteria: HIV-2 infection or co-infection Prior antiretroviral treatment Intolerance, or contraindication to investigational drugs Pregnant or breast-feeding woman, or plan to become pregnant Active untreated opportunistic infections (AIDS-defining illness, category C, CDC, 1993), or malignancies requiring cytotoxic chemotherapy Biological criteria: hemoglobin < 10 G/DL, neutrophil count < 1000/µL, platelets < 50000/µL, creatinine > 2N, ASAT or ALAT > 2.5N, bilirubin > 2N, hypophosphatemia Prevision of poor adherence HBC co-infection (Ag Hbs positive) or HVC co-infection (positive HCV PCR) Liver failure, alcohol abuse Treatment administration not recommended with investigational drugs Interferon, interleukin, or HIV vaccine treatment Informed consent not obtained